

BBS-Bioactive Bone Substitutes Plc publishes the Investor Memorandum and the Basic Information Document related to the Offering and information regarding Subscription undertakings

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 24th of November 2023 at 8.00 a.m. EET

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN PART, DIRECTLY OR INDIRECTLY, IN THE USA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION OR DISTRIBUTION IS UNLAWFUL.

BBS-Bioactive Bone Substitutes Plc ("BBS" or the "Company") has published on 20th of November 2023 that based on authorization granted by the Extraordinary General Meeting on 23rd October 2023, the Board of Directors of BBS has decided to arrange a rights offering totaling approximately EUR 2.63 million (the "Offering"). The Offering consists of a maximum of 6,578,481 new shares (the "Offer Shares").

Subscription undertakings

Certain current shareholders of the Company and one new investor mentioned below have provided subscription undertakings, on the basis of which they have committed to subscribe for approximately 28.8 percent of the Offer Shares offered in the Offering, i.e. they have committed to participate in the Offering with 0.76 million euros. The Company has received the following subscription undertakings to subscribe for Offer Shares in connection with the Offering:

Shareholder subscribing for Offer Shares	Subscription undertaking (shares)	Subscription undertaking (EUR)
Municipality of Reisjärvi	831,000	332,400
Finha Capital Oy	700,000	280,000
Muoraus ja Rappaus Saarimaa Oy	127,500	51,000
Riverfort Global Opportunities PCC Limited	125,000	50,000
Pekka Jalovaara	50,000	20,000
Jyrki Halonen	35,000	14,000
Jarmo Halonen	25,000	10,000
Total	1,893,500	757,400

The Company has not received or requested collaterals from the parties that have committed to subscribe for the Offer Shares in the Offering on the basis of subscription undertakings.

Investor Memorandum and Basic Information Document

BBS-Bioactive Bone Substitutes Plc has published, in connection with the Offering, the Investor Memorandum ("Investor Memorandum") as well as the Basic Information Document in accordance with Chapter 3, Section 2 of the Finnish Securities Markets Act (746/2012, as amended) ("Basic Information Document") with corresponding attachments, both of which are available on the Company's website <https://www.bbs-artebone.fi/investors/share-issue-2023-11/>.

For more information, please contact:

Juliusz Rakowski, CEO
+358 50 448 5132
juliusz.rakowski@bbs-artebone.fi

Certified Advisor:
Nordic Certified Adviser AB,
+46 70 551 67 29,
info@certifiedadviser.se

BBS in brief

BBS -Bioactive Bone Substitutes Plc is an orthobiology company that started its operations in 2003. We have developed a new product for the treatment of complex bone fractures and bone healing issues. Our goal is to provide next-generation medical products for the treatment of bone injuries in orthopedic surgery. In the pharmaceutical industry, the development and research work require perseverance and courage to innovate. Our company is characterized by expertise, innovation, and dedicated employees who are passionate about their work. Our developed product, ARTEBONE®, is in the final stages of product development, and we are seeking the CE marking to enable its commercialization in the EU market. We are based in Oulu with a medical manufacturing facility in Reisjärvi, holding a manufacturing license. The company's headquarters are in Oulu, and we employ more than 20 employees.

BBS has been listed on Nasdaq First North Growth Market Finland since February 2018.

More information: www.bbs-artebone.fi

IMPORTANT NOTICE

This release or the information contained therein shall not be distributed, directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa or the United States. The information contained in this release do not constitute an offer of, or invitation to purchase any securities in any area, where offering, procurement of or selling such securities would be unlawful prior to registration or exemption from registration or any other approval required by the securities regulation in such area. This release is not an offer for sale of securities in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended, and the rules and regulations issued by virtue of it. BBS has not registered, and does not intend to register, any offering of securities in the United States. No actions have been taken to register the shares or the offering anywhere else than in Finland.

The information contained herein shall not constitute an offer of, or invitation to purchase any securities in any jurisdiction. This release is not a prospectus and does not constitute any offer, invitation or investment advice to subscribe for or purchase securities. Investors should not subscribe for or purchase any securities or make any investment decisions referred to herein except on the basis of information contained in the investor memorandum and basic information document issued by BBS.